You have reached the maximum number of Guideline views for today. By creating a free account, you can increase your number of complimentary daily views.
To view this Guideline, please log in to your account. If you do not have an account, you can create one for free by clicking the button below.
Treatment of Latent Tuberculosis Infection
Publication Date: February 14, 2020
Last Updated: March 14, 2022
Recommendations for regimens to treat latent tuberculosis infection
Having trouble viewing table?
Priority rank*
Regimen
Recommendation (strong or conditional)
Evidence (high, moderate, low, or very low)
Preferred
3 mos isoniazid plus rifapentine given once weekly
Strong
Moderate
Preferred
4 mos rifampin given daily
Strong
Moderate (HIV negative)†
Preferred
3 mos isoniazid plus rifampin given daily
Conditional
Very low (HIV negative)
Conditional
Low (HIV positive)
Alternative
6 mos isoniazid given daily
Strong§
Moderate (HIV negative)
Conditional
Moderate (HIV positive)
Alternative
9 mos isoniazid given daily
Conditional
Moderate
* Preferred: excellent tolerability and efficacy, shorter treatment duration, higher completion rates than longer regimens and therefore higher effectiveness; alternative: excellent efficacy but concerns regarding longer treatment duration, lower completion rates, and therefore lower effectiveness.
† No evidence reported in HIV-positive persons.
§ Strong recommendation for those persons unable to take a preferred regimen (e.g., due to drug intolerability or drug-drug interactions).